• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

    4/14/25 4:30:48 PM ET
    $NUTX
    Business Services
    Consumer Discretionary
    Get the next $NUTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bates Jon Christian

    (Last) (First) (Middle)
    6030 S. RICE AVE., SUITE C

    (Street)
    HOUSTON TX 77081

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Nutex Health, Inc. [ NUTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/01/2025 M 111(1) A $0(1) 2,388 D
    Common Stock 03/01/2025 M 1,500(1) A $0(1) 3,888 D
    Common Stock 04/08/2025 P 1,000 A $81.81 4,888 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units $0(1) 03/10/2025 M 3,500(1) 03/01/2026(2) 03/01/2028(2) Common Stock 3,500 $0 6,500 D
    Explanation of Responses:
    1. Restricted stock units convert into common stock on a one-for-one basis.
    2. On March 10, 2025, the Reporting Person was granted 3,500 RSUs, which vest in three equal installments on March 1, 2026, March 1, 2027, and March 1, 2028.
    /s/ Jon Bates 04/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NUTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUTX

    DatePrice TargetRatingAnalyst
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    9/18/2024$45.00Buy
    Maxim Group
    2/22/2023$3.00Outperform
    Northland Capital
    More analyst ratings

    $NUTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nutex Health Inc.

      SC 13G - Nutex Health, Inc. (0001479681) (Subject)

      11/14/24 11:02:17 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Nutex Health Inc. (Amendment)

      SC 13G/A - Nutex Health, Inc. (0001479681) (Subject)

      9/26/23 4:26:07 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Nutex Health Inc.

      SC 13G - Nutex Health, Inc. (0001479681) (Subject)

      7/7/23 5:03:39 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NUTEX HEALTH ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

      HOUSTON, April 22, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Scott J. Saunders, and Kelvin Spears, MD, to its Board of Directors.  They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment. The Board has determined that Mr. Saunders satisfies the current independent director standards established by the rules of The Nasdaq Stock Market. Mr. Saunders will s

      4/22/24 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JOSHUA DETILLIO AS ITS NEW CHIEF OPERATING OFFICER

      HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Joshua DeTillio as the Company's Chief Operating Officer effective on or about October 2, 2023. Mr. DeTillio is an experienced healthcare leader with over 20 years of hospital experience and 12 years as a CEO in investor-owned, publicly traded companies. He has demonstrated success in collaborating with and leading boards and physicians to drive growth, improve c

      9/5/23 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JON BATES AS ITS NEW CHIEF FINANCIAL OFFICER

      HOUSTON, June 10, 2022 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, today announced the appointment of Jon Bates as the Company's Chief Financial Officer effective on or about June 30, 2022. On May 3, 2022, Michael Bowen notified the company that he intends to retire as Chief Financial Officer of the Company. In connection with Mr. Bowen's retirement, the Company's Board formed a search committee.  On June 8, 2022, the Company announced the appointme

      6/10/22 6:00:00 AM ET
      $NUTX
      $USPH
      Business Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $NUTX
    SEC Filings

    See more
    • Nutex Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Nutex Health, Inc. (0001479681) (Filer)

      5/13/25 4:31:29 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form 10-Q filed by Nutex Health Inc.

      10-Q - Nutex Health, Inc. (0001479681) (Filer)

      5/13/25 4:28:53 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form 424B3 filed by Nutex Health Inc.

      424B3 - Nutex Health, Inc. (0001479681) (Filer)

      5/2/25 4:35:17 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Financials

    Live finance-specific insights

    See more
    • Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

      HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=com

      5/7/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH SCHEDULES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

      HOUSTON, March 17, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of the stock market on March 27th, 2025. The Company will discuss those results on a conference call on Friday, March 28st, 2025, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://viavid.webcasts.com/starthere.jsp?ei=1706653&tp_key=5e3e4c2f6

      3/17/25 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH SCHEDULES 2024 THIRD QUARTER FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

      HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691722&tp_key=bfd69ce

      11/5/24 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Financial Officer Bates Jon Christian bought $28,970 worth of shares (1,350 units at $21.46), increasing direct ownership by 146% to 2,277 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      8/26/24 11:54:30 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Operating Officer Detillio Joshua bought $10,800 worth of shares (20,000 units at $0.54), increasing direct ownership by 214% to 29,333 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      6/13/24 11:50:03 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Nutex Health with a new price target

      Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously

      11/12/24 8:15:57 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Maxim Group initiated coverage on Nutex Health with a new price target

      Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00

      9/18/24 8:12:45 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Northland Capital initiated coverage on Nutex Health with a new price target

      Northland Capital initiated coverage of Nutex Health with a rating of Outperform and set a new price target of $3.00

      2/22/23 9:08:40 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Director Spears Kelvin converted options into 143 shares and covered exercise/tax liability with 34 shares, increasing direct ownership by 0.34% to 31,992 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:15:36 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Operating Officer Detillio Joshua converted options into 2,125 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 35% to 6,481 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:01:59 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8%NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET LOSS OF $0.4 MILLION IN Q1 2024DILUTED EPS OF $2.56 PER SHARE VERSUS $(0.08) PER SHARE IN Q1 2024EBITDA OF $43.1 MILLION VERSUS $7.1 MILLION IN EBITDA IN Q1 2024, AN INCREASE OF 507.0%ADJUSTED EBITDA OF $72.8 MILLION VERSUS $(0.4) MILLION IN Q1 2024NET CASH FROM OPERATING ACTIVITIES OF $51.0 MILLIONCOMPANY BELIEVES ITS ARBITRATION EFFORTS THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS HAVE RESULTED IN MORE FAIR AND REASONABLE PAYMENTSHOUSTON, May 13, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NA

      5/13/25 5:43:00 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

      HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=com

      5/7/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      FULL YEAR 2024 HIGHLIGHTS: TOTAL REVENUE OF $479.9 MILLION VERSUS $247.6 MILLION IN 2023, AN INCREASE OF 93.8%NET INCOME OF $52.2 MILLION VERSUS NET LOSS OF $45.8 MILLION IN 2023DILUTED EPS OF $9.71 PER SHARE VERSUS $(10.39) PER SHARE IN 2023EBITDA OF $98.4 MILLION VERSUS $(22.5) MILLION IN EBITDA IN 2023ADJUSTED EBITDA OF $123.7 MILLION VERSUS $10.8 MILLION IN 2023, AN INCREASE OF 1,045.4%NET CASH FROM OPERATING ACTIVITIES OF $23.2 MILLIONCOMPANY BELIEVES ITS ARBITRATION EFFORTS, THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS, HAS RESULTED IN MORE EQUITABLE PAYMENTSHOUSTON, March 31, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physicia

      3/31/25 4:30:00 PM ET
      $NUTX
      Business Services
      Consumer Discretionary